Isoxazole N-linked carbamoyl cyclohexyl acids as LPA antagonists

A compound according to Formula (Ia):

• or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, wherein
• X1, X2 and X3 are each independently CR6;
• Y1 is NR3;
• Y2 is
• Y3 is O;
• L is a covalent bond or CH2;
• R1 is —C(O)OR10;
• R3 and R4a are independently hydrogen, C1-6 alkyl, haloalkyl, hydroxyalkyl, aminoalkyl, alkoxyalkyl, haloalkoxyalkyl, alkoxy, or haloalkoxy;
• R4 is C1-10 alkyl, C1-10 deuterated alkyl, C1-10 haloalkyl, C1-10 alkenyl, C3-8 cycloalkyl, 6 to 10-membered aryl, —(C1-6 alkylene)-(C3-8 cycloalkyl), or —(C1-6 alkylene)-(6 to 10-membered aryl);
• wherein each of the alkyl, alkylene, alkenyl, cycloalkyl, and aryl, by itself or as part of other moiety, is independently substituted with 0 to 3 R8;
• R5 and R6 are each independently hydrogen, halo, cyano, hydroxyl, amino, C1-6 alkyl, alkylamino, haloalkyl, hydroxyalkyl, aminoalkyl, alkoxyalkyl, haloalkoxyalkyl, alkoxy, or haloalkoxy;
• R8 are each independently deuterium, halo, hydroxyl, amino, cyano, C1-6 alkyl, C1-6 deuterated alkyl, C2-6 alkenyl, C2-6 alkynyl, alkylamino, haloalkyl, hydroxyalkyl, aminoalkyl, alkoxyalkyl, haloalkoxyalkyl, alkoxy, haloalkoxy, phenyl, or 5 to 6 membered heteroaryl;
• or alternatively, two R8, taken together with the atom(s) to which they are attached, form a 3 to 6-membered carbocyclic ring each of which is independently substituted with 0 to 3 R12;
• R10 is hydrogen or C1-10 alkyl;
• and
• R12 is halo, cyano, hydroxyl, amino, C1-6 alkyl, alkylamino, haloalkyl, hydroxyalkyl, aminoalkyl, alkoxyalkyl, haloalkoxyalkyl, alkoxy, haloalkoxy, phenyl, or 5 to 6 membered heteroaryl.